Filer Snapshot

GILEAD SCIENCES, INC.

CIK 0000882095. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

206

Latest filing

16 Jun 2026

Industry

Biological Products, (No Disgnostic Substances)

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q1 2026. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13F portfolio Save page

Largest parsed holding

ACLX

$771.68M reported value

Open holding

13D/G large stake

ASMB

22 May 2026 · 25% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Forms 3/4/5

4 filed on 16 Jun 2026 for CIK 0000882095.

View source filing
Listed symbols
GILD on Nasdaq
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

13F portfolio$2.12B

Quarterly institutional holdings reported on Form 13F; not total AUM.

Forms 3/4/5 positions$916.75M

Reporting-owner positions with enough filing detail to estimate value.

Latest reported 13F value

13F
$2.12B

Reported market value from the latest parsed Form 13F information table; this is not total assets under management.

Source: SEC Form 13FScope: U.S.-listed equity holdings

Forms 3/4/5 position value

3/4/5
$916.75M

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Source: Forms 3/4/5Confidence: Estimated when price data is available

Largest 13F holdings

13F
ACLX RCUS GLPG ASMB KYTX
+1 moreXLO

Largest symbols in the latest parsed Form 13F information table.

Freshness: Latest parsed 13F period

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

ACLX RCUS ASMB XLO LPTX HOOK ALVR

Largest 13F holdings

Largest symbols in the latest parsed Form 13F information table.

ACLX RCUS GLPG ASMB KYTX XLO

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

GLPG ACLX RCUS ASMB

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

XLO KLRS IKNA CYPH
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 2 identity fields
SEC industry group
Biological Products, (No Disgnostic Substances) (Office of Life Sciences)
Business address
333 Lakeside Dr, Foster City, CA, 94404
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Incorporated in
DE
Fiscal year end
31 December

Filer intelligence

What SEC filings say about GILEAD SCIENCES, INC.

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Open 13F portfolio Save filer

Quick read

  • Latest parsed 13F shows $2.12B across 6 reported holdings for Q1 2026.
  • Largest parsed 13F holding: ACLX at $771.68M.
  • 5 recent 13D/G stake rows found; top row is ASMB at 25% ownership.
  • Forms 3/4/5 show insider context for ACLX worth $371.44M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 6 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 5 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 5 rows

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q1 2026 - 08 May 2026

Top 5 concentration

100%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$2.11B

Compared with $2.12B total 13F value.

Top 5 net change

$0

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest trim: XLO

ACLX RCUS GLPG ASMB KYTX Other holdings

ACLX

36.4%

Arcellx Inc

$771.68M

RCUS

32.1%

Arcus Biosciences Inc

$678.77M

GLPG

23.7%

Galapagos NV

$501.22M

ASMB

5.9%

Assembly Biosciences Inc

$125.02M

KYTX

1.7%

Kyverna Therapeutics Inc

$35.61M

13D/G large-stake context

ASMB

22 May 2026 · Common Stock, par value $0.001

25%
Issuer page 13D/G history

ACLX

28 Apr 2026 · Common Stock, par value $0.001

100%
Issuer page 13D/G history

XLO

31 Dec 2025 · Common Stock, par value $0.0001 per share

20%
Issuer page 13D/G history

CYPH

31 Dec 2025 · Common Stock, par value $0.001 per share

0%
Issuer page 13D/G history

Forms 3/4/5 insider context

ACLX

28 Dec 2023 · 10% owner

$371.44M
Issuer page Owner page

RCUS

18 Feb 2025 · 10% owner

$345.67M
Issuer page Owner page

ASMB

26 May 2026 · 10% owner

$138.11M
Issuer page Owner page

XLO

13 Feb 2026 · 10% owner

$21.6M
Issuer page Owner page

Latest update

What changed recently for GILEAD SCIENCES, INC.

Ownership report updated

Latest ownership report period: 26 May 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

27 May 2026

Page type

Ownership filings

Latest period

26 May 2026

Ownership context was refreshed from SEC Forms 3/4/5 filed on 27 May 2026.

Open ownership filings Browse recent public updates

Benchmark Context

Benchmark context for this company

GILEAD SCIENCES, INC. has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest ownership report period: 26 May 2026. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 07 May 2026.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0000882095 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
206
First seen
29 Dec 2023
Latest filing
16 Jun 2026
Entity
Company

Observed form types

10-K 10-Q 13F-HR 3 4 SCHEDULE 13D SCHEDULE 13D/A SCHEDULE 13G/A

CIK-linked evidence first

GILEAD SCIENCES, INC. SEC filings GILEAD SCIENCES, INC. 13F portfolio GILEAD SCIENCES, INC. 13D/G history GILEAD SCIENCES, INC. owner filings GILEAD SCIENCES, INC. insider transactions Open SEC filing index

Industry context: Biological Products, (No Disgnostic Substances).

Latest Filings

Showing the latest 12 of 206 SEC filings for GILEAD SCIENCES, INC..

Open full filing history
4

4 filing

Filing date
16 Jun 2026
Reporting date
15 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
16 Jun 2026
Reporting date
15 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
11 Jun 2026
Reporting date
10 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
11 Jun 2026
Reporting date
10 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
11 Jun 2026
Reporting date
10 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
11 Jun 2026
Reporting date
10 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
11 Jun 2026
Reporting date
10 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
02 Jun 2026
Reporting date
01 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
27 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 May 2026
Reporting date
15 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 May 2026
Reporting date
15 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
08 May 2026
Reporting date
31 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .